Newspatrolling.com News cum Content Syndication Portal Online
Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations
Bengaluru, February 10, 2025: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in pre-filled syringes across all major strengths. This approval reinforces the company’s presence in Indonesia and aligns with its broader expansion strategy in Southeast Asia.
“Indonesia has the highest burden of cardiovascular diseases in the region, driven by an aging population and lifestyle changes. Our Enoxaparin will offer a cost-effective solution to manage clot-related conditions,” said Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.
Enoxaparin, a key anticoagulant, helps prevent and treat blood clots, reducing the risk of deep vein thrombosis and pulmonary embolism. The global Enoxaparin market, valued at USD 3.3 billion in 2023, is projected to reach USD 5.4 billion by 2032, growing at a CAGR of 7.1%–7.9%. Venus Remedies, with an annual production capacity exceeding 10 million units at its autonomous robotic facility, is well-positioned to capture a significant market share in Southeast Asia and beyond.
The Southeast Asian anticoagulant market is expected to reach USD 550.7 million by 2029, growing at 7.84% CAGR, while Indonesia’s market alone is projected to expand at 7.72% CAGR, reaching USD 140.3 million by 2029.
“India’s pharmaceutical exports to Indonesia were valued at USD 84.53 million in 2023, reflecting strong trade ties between the two nations,” said Mrs. Aditi Chaudhary, President, International Business, Venus Remedies. “While anticoagulants remain a key focus, we are also expanding into other therapeutic areas to address critical medical needs and improve patient outcomes with affordable generic drugs.”
With over a dozen global marketing authorizations for Enoxaparin, Venus Remedies continues to strengthen its presence in international markets, reinforcing its commitment to advancing accessible healthcare solutions.
